Background: Nonrheumatic valvular heart disease (NRVD) is increasingly becoming a significant public health concern, particularly among older people. In the context of population aging, a detailed report on the epidemiological trends of NRVD is crucial for policymakers to effectively allocate health care resources. This study aimed to explore these trends using data from the GBD (Global Burden of Disease) 2019 study. Methods and Results: We assessed the changing trends of the incidence, mortality, and disability‐adjusted life years rates for NRVD by calculating the estimated annual percentage change for each. Additionally, we examined the impact of a region's level of social development on NRVD epidemiological trends and identified key risk factors contributing to NRVD‐related deaths. Between 1990 and 2019, the global incidence of NRVD showed a gradual increase, with an estimated annual percentage change of 0.39 (95% CI, 0.30–0.48). The data revealed that women and older people are more likely to develop NRVD. High‐sociodemographic index countries exhibited higher age‐standardized incidence and mortality rates compared with low‐ and middle‐sociodemographic index countries. The most significant risk factor for NRVD‐related mortality was identified as high systolic blood pressure. Conclusions: Over the past 3 decades, the burden of NRVD has intensified, indicating a need for more health care resources to address this issue, which is closely associated with an aging population. Currently, high‐sociodemographic index countries report the highest incidences and deaths due to NRVD. However, low‐ and middle‐sociodemographic index countries should also implement measures to manage the rapidly increasing burden of NRVD.
9 June 2023 in Arrhythmia and Electrophysiology Review
Syncope is defined by transient and spontaneous loss of consciousness with rapid recovery. Vasovagal syncope (VVS) is the most common form of syncope and is strongly associated with hypervagotonia. There is, however, a lack of effective therapies for VVS. Cardioneuroablation (CNA) is an emerging and promising intervention for VVS with favourable outcomes. CNA has been shown to suppress excessive excitation of vagal activity through ablating the cardiac ganglionated plexi. CNA in the management of VVS requires more structured and comprehensive studies and several issues concerning patient selection, selection of ablation targets, ablation endpoints and the long-term effect of CNA are yet to be determined. This review describes its clinical applications and future directions based on current research data and the authors’ own experiences.
The aim of this study was to investigate the outcomes of catheter ablation (CA) in preventing arrhythmic events among patients with symptomatic Brugada syndrome (BrS) who declined implantable cardioverter defibrillator (ICD) implantation. A total of 40 patients with symptomatic BrS were included in the study, of which 18 refused ICD implantation and underwent CA, while 22 patients received ICD implantation. The study employed substrate modification (including endocardial and epicardial approaches) and ventricular fibrillation (VF)-triggering pre-mature ventricular contraction (PVC) ablation strategies. The primary outcomes were a composite endpoint consisting of episodes of VF and sudden cardiac death during the follow-up period. The study population had a mean age of 43.8 ± 9.6 years, with 36 (90.0%) of them being male. All patients exhibited the typical Type 1 BrS electrocardiogram pattern, and 16 (40.0%) were carriers of an SCN5A mutation. The Shanghai risk scores were comparable between the CA and the ICD groups (7.05 ± 0.80 vs. 6.71 ± 0.86, P = 0.351). Ventricular fibrillation–triggering PVCs were ablated in 3 patients (16.7%), while VF substrates were ablated in 15 patients (83.3%). Epicardial ablation was performed in 12 patients (66.7%). During a median follow-up of 46.2 (17.5–73.7) months, the primary outcomes occurred more frequently in the ICD group than in the CA group (5.6 vs. 54.5%, Log-rank P = 0.012). Catheter ablation is an effective alternative therapy for improving arrhythmic outcomes in patients with symptomatic BrS who decline ICD implantation. Our findings support the consideration of CA as an alternative treatment option in this population. The left figure shows an example of Brugada syndrome phenotype abolition by catheter ablation (CA). After the epicardial ablation, the maximum amplitude of ST elevation of Lead V1 was significantly decreased (0.420–0.244 mV), and the local low-voltage area was nearly eliminated. The right figure illustrates the Kaplan–Meier curve of arrhythmic events (cardiac death/ventricular fibrillation) for patients received CA vs. implantable cardioverter defibrillator.
15 November 2023 in Journal of Medical Internet Research
Background: Life-threatening ventricular arrhythmias (LTVAs) are main causes of sudden cardiac arrest and are highly associated with an increased risk of mortality. A prediction model that enables early identification of the high-risk individuals is still lacking. Objective: We aimed to build machine learning (ML)–based models to predict in-hospital mortality in patients with LTVA. Methods: A total of 3140 patients with LTVA were randomly divided into training (n=2512, 80%) and internal validation (n=628, 20%) sets. Moreover, data of 2851 patients from another database were collected as the external validation set. The primary output was the probability of in-hospital mortality. The discriminatory ability was evaluated by the area under the receiver operating characteristic curve (AUC). The prediction performances of 5 ML algorithms were compared with 2 conventional scoring systems, namely, the simplified acute physiology score (SAPS-II) and the logistic organ dysfunction system (LODS). Results: The prediction performance of the 5 ML algorithms significantly outperformed the traditional models in predicting in-hospital mortality. CatBoost showed the highest AUC of 90.5% (95% CI 87.5%-93.5%), followed by LightGBM with an AUC of 90.1% (95% CI 86.8%-93.4%). Conversely, the predictive values of SAPS-II and LODS were unsatisfactory, with AUCs of 78.0% (95% CI 71.7%-84.3%) and 74.9% (95% CI 67.2%-82.6%), respectively. The superiority of ML-based models was also shown in the external validation set. Conclusions: ML-based models could improve the predictive values of in-hospital mortality prediction for patients with LTVA compared with traditional scoring systems.
Catheter ablation (CA) is increasingly recognized as an effective treatment for ventricular tachycardia (VT) in myocarditis patients, although current evidence is based on less robust data. The purpose of this study was to confirm CA's efficacy in reducing VT recurrence and to identify arrhythmic risk factors in biopsy-proven myocarditis patients. In this dual-center, retrospective study, we included 50 patients with biopsy-proven myocarditis and VT. They were divided into 2 groups: CA (n = 23) and non-CA (n = 27), with the primary endpoint being VT recurrence at 1-year follow-up. The average age of participants was 40.8 ± 14.9 years; 48% were men. Over a median 371-day follow-up, 28 (56%) experienced VT recurrence, with 8 patients (35%) in the CA group and 20 patients (74%) in the non-CA group. Kaplan-Meier analysis showed that the rate of VT recurrence in the CA group was significantly lower than in the non-CA group (log-rank P = 0.009). However, this difference was not found in patients with acute myocarditis. Multivariable analysis revealed a significant correlation between the acute stage of myocarditis and VT recurrence in both the general cohort (HR: 3.02; 95% CI: 1.11-8.21; P = 0.031) and the subset undergoing CA (HR: 11.4; 95% CI: 1.02-127.5; P = 0.048). CA is significantly associated with reduced VT recurrence in biopsy-proven myocarditis, albeit this association is not observed in cases of acute myocarditis. The acute stage of myocarditis is independently associated with an increased risk of VT recurrence.
Cardiovascular diseases (CVDs) account for a large and increasing health burden worldwide, as shown in the Global Burden of Disease Study 2021. However, there has been no comprehensive assessment of CVDs in Asia, which bears the largest population globally. This study sought to evaluate the burden of CVD in Asia from 1990 to 2021. Mortality, prevalence, and disability-adjusted life years (DALYs) along with their age-standardized rates (ASRs) per 100,000 population from 1990 to 2021 were used to measure the CVDs burden. Further subanalyses were conducted based on age group and sex. In 2021, CVDs caused an estimated 11.9 million deaths (95% uncertainty interval [UI]: 10.9-12.9 million deaths), 340.4 million prevalent cases (95% UI: 315.1-366.9 million prevalent cases), and 270.4 million DALYs (95% UI: 251.6-290.2 million DALYs). Although the ASR of prevalence slightly increased from 1990 to 2021 with a percentage change of 5.7% (95% UI: 3.9%-8.1%), the ASRs of death and DALYs were significantly decreased, with percentage changes of -28.2% (95% UI: -42.2% to -12.5%) and -37.8% (95% UI: -50.5% to -24.3%), respectively. The Asian burden of CVDs was higher in males and the elderly. The primary contributors to DALYs across Asia were ischemic heart disease, stroke, and hypertensive heart disease. Burden of CVDs in Asia remains substantial. Certain populations, including males and the elderly, experienced a heavier burden of CVDs.